197 results on '"Gebo, Kelly A"'
Search Results
2. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
3. Discordant Performance of Mpox Serological Assays
4. Accuracy of Provider Predictions of Viral Suppression Among Adolescents and Young Adults With HIV in an HIV Clinical Program
5. Risk Factors for Hospitalization and Effect of Immunosuppression on Clinical Outcomes Among an Urban Cohort of Patients With Mpox
6. 2670. Sexual Health Evaluation Among People Tested for Mpox in an Urban Health System
7. 401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy
8. 2664. Patient Perspectives on Care Outcomes and Interactions with an Urban Emergency Department Health System for Mpox: A Quality Improvement Study
9. 2505. Using an Electronic Medical Record Alert to Screen Inpatient Encounters for People with Hepatitis C
10. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
11. Hospital Readmissions among Persons with HIV in the United States and Canada, 2005–2018: A Collaboration of Cohort Studies
12. Impact of subgroup-specific heterogeneities and dynamic changes in mortality rates on forecasted population size, deaths, and age distribution of persons receiving antiretroviral treatment in the United States: a computer simulation study
13. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study
14. Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us Research Program
15. Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
16. The association of a scholarly concentrations program with medical students’ matched residencies
17. Orthopoxvirus-Specific T-Cell Responses in Convalescent Mpox Patients
18. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
19. Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample
20. Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine
21. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
22. Mpox in people with advanced HIV infection: a global case series
23. Telemedicine Use Among People With HIV in 2021: The Hybrid-Care Environment
24. Design and Implementation of the All of Us Research Program COVID-19 Participant Experience (COPE) Survey
25. Early Treatment, Inflammation and Post-COVID Conditions
26. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019 (COVID-19)
27. Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
28. Reply to Steele et al
29. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US
30. Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV
31. The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox
32. A Growing Number of Men Who Have Sex With Men Aging With HIV (2021–2031): A Comparison of Two Microsimulation Models
33. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection
34. Achieving a Representative Sample of Asian Americans in Biomedical Research Through Community-Based Approaches: Comparing Demographic Data in the All of Us Research Program With the American Community Survey
35. The changing prevalence of anemia and risk factors in people with HIV in North America who have initiated ART, 2007–2017
36. The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum
37. The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030
38. Absence of pathogenic viruses in COVID ‐19 convalescent plasma
39. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
40. Time Between Viral Loads for People With HIV During the COVID-19 Pandemic
41. The All of Us Research Program: Data quality, utility, and diversity
42. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial
43. Telemedicine Use Among People with HIV in 2021: The Hybrid-Care Environment
44. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
45. Designing an electronic medical record alert to identify hospitalised patients with HIV: successes and challenges
46. Early Outpatient Treatment for Covid-19 with Convalescent Plasma
47. How do I implement an outpatient program for the administration of convalescent plasma for COVID ‐19?
48. Epidemiology of atrial fibrillation in the All of Us Research Program
49. Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection
50. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.